According to reports from The Washington Post, BBC, and CNN, a US federal appeals court ruled on May 1 to temporarily block the FDA’s rules allowing mail-order access to the abortion drug mifepristone. The decision has significant implications for reproductive healthcare access for millions of women across the country.

The ruling marks the latest development in a long-running legal challenge by anti-abortion groups against FDA policy. The appeals court determined that the FDA had not sufficiently evaluated safety implications when expanding access to mifepristone, and therefore temporarily suspended regulations that permitted mail-order prescriptions and telehealth prescriptions for the drug.

Following the ruling, reproductive rights advocacy groups responded swiftly, announcing plans for an immediate emergency appeal to the Supreme Court. “This ruling will directly harm women living in states where abortion clinics are scarce or where abortion is banned,” the ACLU’s Reproductive Freedom Project director said in a statement.

The FDA had previously allowed mail-order access to mifepristone, which enabled women living far from abortion clinics—particularly in rural areas—to more easily obtain safe medication abortion services. It is estimated that approximately one-third of medication abortions were completed via mail under the previous regulations.

The Guardian reported that this ruling comes amid ongoing state-level legislative challenges to abortion rights in the United States. Since the Supreme Court overturned Roe v. Wade in 2022, multiple states have implemented or attempted to implement strict abortion restrictions.

Legal experts suggest the case will likely be appealed to the Supreme Court once again. The Court had previously ruled in favor of preserving mifepristone access in similar cases, but the current composition of the Court introduces uncertainty about the potential outcome.

A White House spokesperson said the administration was “deeply disappointed” by the ruling and stated it would pursue all available legal avenues to protect women’s healthcare access.

Sources: The Washington Post, BBC, CNN

A US federal appeals court issued a temporary order on Thursday blocking the Food and Drug Administration’s (FDA) rule that allowed women to obtain the abortion drug mifepristone by mail, CNN and The New York Times reported. The ruling will have significant implications for medication abortion accessibility across the country.

The Ruling

The appeals court’s temporary order effectively suspends the FDA’s expanded policy that permitted certified healthcare providers to mail mifepristone to patients. Mifepristone is the primary drug used in medication abortions, which currently represent the most common method for the procedure in the United States.

The ruling is the latest development in an ongoing legal campaign by anti-abortion organizations and state governments challenging the FDA’s regulatory decisions on the drug. Opponents argue that mailing prescription abortion drugs poses safety risks and should be subject to stricter oversight.

Impact

The mifepristone-misoprostol medication abortion regimen is currently the most prevalent method for terminating early pregnancies in the US. The FDA’s previous rule allowing mail distribution of the drug significantly expanded access for women in remote areas and states with restrictive abortion laws.

The temporary order will reintroduce barriers to medication access for this population, particularly in states that have implemented strict abortion restrictions.

Reactions

Pro-choice organizations strongly condemned the ruling, arguing it infringes on personal medical autonomy. Related legal groups have indicated they will continue pursuing legal avenues to defend the FDA’s original policy.

Conversely, anti-abortion groups welcomed the ruling as an interim victory and called on the court to permanently overturn the FDA’s mail distribution rule.

Legal Background

The FDA’s regulatory approach to mifepristone has undergone several changes in recent years. In 2021, the agency eliminated the in-person dispensing requirement, allowing the drug to be distributed by mail. Since then, anti-abortion states and organizations have filed multiple lawsuits seeking to reverse this policy change.

It remains unclear whether the appeals court’s temporary order will persist and how the case will proceed through higher levels of the judicial system.

Source: CNN, The New York Times